Celcuity Inc. 10-Q Summary: Period Ended September 30, 2017
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2017, for Celcuity Inc., a cellular analysis company developing diagnostic tests to identify cancer sub-types. The company operates the proprietary CELx platform, which uses living tumor cells to evaluate cell signaling pathways. As of the reporting date, Celcuity had not generated any revenue. A significant corporate event occurred during the period: on September 15, 2017, Celcuity LLC converted to a Delaware corporation (Celcuity Inc.), and on September 22, 2017, the company completed its Initial Public Offering (IPO), listing on Nasdaq under the symbol "CELC."
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2017 | Nine Months Ended Sep 30, 2017 | Balance Sheet (Sep 30, 2017) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(1,763,976) | $(4,527,542) | N/A |
| Operating Expenses | $1,529,393 | $4,128,912 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $32,304,145 |
| Total Assets | N/A | N/A | $33,146,545 |
| Total Liabilities | N/A | N/A | $336,447 |
| Stockholders' Equity | N/A | N/A | $32,810,098 |
Cash Flow (Nine Months Ended Sep 30, 2017):
- Net cash used in operating activities: $(3,838,020)
- Net cash used in investing activities: $(448,496)
- Net cash provided by financing activities: $30,734,313 (driven by IPO and convertible notes)
Material Changes vs. Prior Period
- Capital Structure: The company transitioned from a private LLC to a public corporation. The IPO raised approximately $23.3 million in net proceeds. Additionally, $8.3 million in convertible promissory notes were converted into 881,911 shares of common stock.
- Liquidity: Cash and cash equivalents increased from $5.9 million at December 31, 2016, to $32.3 million at September 30, 2017, primarily due to financing activities.
- Expenses: Total operating expenses increased 74% for the three months and 71% for the nine months compared to the prior year periods. This was driven by increased employee-related costs, stock-based compensation, and clinical trial start-up costs.
- Interest Expense: Interest expense of $264,905 (three months) and $451,664 (nine months) was recorded in 2017 due to the amortization of debt discounts and financing costs related to convertible notes. No interest expense was recorded in the comparable 2016 periods.
Outlook, Risks, and Management Commentary
Outlook and Guidance: Management expects to continue incurring significant losses as it advances the development of the CELx platform and commercializes the CELx HSF Test for HER2-negative breast cancer. The company plans to launch additional tests for 14 other potential cancer sub-types over the next few years. Based on current cash on hand ($32.5 million), management believes it has sufficient liquidity to fund operations for at least the next 24 months.
Risks and Contingencies:
- Revenue Generation: The company has no revenue to date and relies on future partnerships with pharmaceutical companies and commercialization of diagnostic tests.
- Clinical Trials: Success depends on the results of a prospective clinical trial with Genentech and the NSABP, with interim results expected 10-12 months after the first patient enrollment.
- Regulatory and Market: Risks include uncertainty regarding market acceptance, reimbursement by third-party payors, and the complexity of developing and validating new diagnostic tests.
Key Facts for Investor Verification
- Revenue Status: Verify that the company has generated zero revenue to date and remains pre-commercial.
- Burn Rate: Confirm the rate of cash consumption from operations (approx. $3.8 million used in nine months) against the $32.3 million cash balance.
- Clinical Trial Timeline: Monitor the enrollment status and timeline for the HER2-negative breast cancer clinical trial, as this is a critical milestone for future revenue.
- Dilution: Review the impact of outstanding warrants (373,539 shares) and stock options (478,453 shares) on future share count.
- Debt Conversion: Confirm that all convertible promissory notes were fully converted to equity upon the IPO closing, leaving no outstanding debt principal.